ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Neurofibromatosis Type 1 Market Insights, Forecast to 2030
Published Date: December 2024
|
Report Code: QYRE-Auto-23X8187
Home | Market Reports | Health| Health Conditions| Genetic Disorders
Global Neurofibromatosis Type 1 Market Insights and Forecast to 2028
BUY CHAPTERS

Global Neurofibromatosis Type 1 Market Insights, Forecast to 2030

Code: QYRE-Auto-23X8187
Report
December 2024
Pages:78
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Astrazeneca plc
Merck

Neurofibromatosis Type 1 Market

NF1 is a debilitating genetic condition that affects one in every 3,000 to 4,000 individuals. It is caused by a spontaneous or inherited mutation in the NF1 gene and is associated with many symptoms, including soft lumps on and under the skin (cutaneous neurofibromas) and skin pigmentation (so-called ‘café au lait’ spots) and, in 30-50% of patients, tumours develop on the nerve sheaths (plexiform neurofibromas). 
The global Neurofibromatosis Type 1 market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Neurofibromatosis Type 1 is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The China market for Neurofibromatosis Type 1 is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The Europe market for Neurofibromatosis Type 1 is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The global key manufacturers of Neurofibromatosis Type 1 include AstraZeneca and Merck etc. In 2023, the global top five players had a share approximately % in terms of revenue.
Report Covers:
This report presents an overview of global market for Neurofibromatosis Type 1, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Neurofibromatosis Type 1, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Neurofibromatosis Type 1, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Neurofibromatosis Type 1 sales, revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Neurofibromatosis Type 1 market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type, and by Application, sales, revenue, and price, from 2019 to 2030. Evaluation and forecast the market size for Neurofibromatosis Type 1 sales, projected growth trends, production technology, application and end-user industry.
Market Segmentation

Scope of Neurofibromatosis Type 1 Market Report

Report Metric Details
Report Name Neurofibromatosis Type 1 Market
Segment by Type
  • 10 mg
  • 25 mg
Segment by Application
  • Hospitals
  • Clinics
  • Others
Segment by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, and by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Sales (consumption), revenue of Neurofibromatosis Type 1 in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 3: Detailed analysis of Neurofibromatosis Type 1 manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: North America (US & Canada) by Type, by Application and by country, sales, and revenue for each segment.
  • Chapter 7: Europe by Type, by Application and by country, sales, and revenue for each segment.
  • Chapter 8: China by Type, and by Application, sales, and revenue for each segment.
  • Chapter 9: Asia (excluding China) by Type, by Application and by region, sales, and revenue for each segment.
  • Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, sales, and revenue for each segment.
  • Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Neurofibromatosis Type 1 sales, revenue, price, gross margin, and recent development, etc.
  • Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
  • Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 14: The main points and conclusions of the report.

FAQ for this report

What are the Application segmentation covered in the Neurofibromatosis Type 1 Market report?

Ans: The Applications covered in the Neurofibromatosis Type 1 Market report are Hospitals, Clinics, Others

What are the Type segmentation covered in the Neurofibromatosis Type 1 Market report?

Ans: The Types covered in the Neurofibromatosis Type 1 Market report are 10 mg, 25 mg

Recommended Reports

Rare Disease Markets

Neurodegenerative Therapies

Genetic Disorder Diagnosis

1 Study Coverage
1.1 Neurofibromatosis Type 1 Product Introduction
1.2 Market by Type
1.2.1 Global Neurofibromatosis Type 1 Market Size Growth Rate by Type, 2019 VS 2023 VS 2030
1.2.2 10 mg
1.2.3 25 mg
1.3 Market by Application
1.3.1 Global Neurofibromatosis Type 1 Market Size Growth Rate by Application, 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Neurofibromatosis Type 1 Sales Estimates and Forecasts 2019-2030
2.2 Global Neurofibromatosis Type 1 Revenue by Region
2.2.1 Global Neurofibromatosis Type 1 Revenue by Region: 2019 VS 2023 VS 2030
2.2.2 Global Neurofibromatosis Type 1 Revenue by Region (2019-2024)
2.2.3 Global Neurofibromatosis Type 1 Revenue by Region (2025-2030)
2.2.4 Global Neurofibromatosis Type 1 Revenue Market Share by Region (2019-2030)
2.3 Global Neurofibromatosis Type 1 Sales Estimates and Forecasts 2019-2030
2.4 Global Neurofibromatosis Type 1 Sales by Region
2.4.1 Global Neurofibromatosis Type 1 Sales by Region: 2019 VS 2023 VS 2030
2.4.2 Global Neurofibromatosis Type 1 Sales by Region (2019-2024)
2.4.3 Global Neurofibromatosis Type 1 Sales by Region (2025-2030)
2.4.4 Global Neurofibromatosis Type 1 Sales Market Share by Region (2019-2030)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufactures
3.1 Global Neurofibromatosis Type 1 Sales by Manufacturers
3.1.1 Global Neurofibromatosis Type 1 Sales by Manufacturers (2019-2024)
3.1.2 Global Neurofibromatosis Type 1 Sales Market Share by Manufacturers (2019-2024)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Neurofibromatosis Type 1 in 2023
3.2 Global Neurofibromatosis Type 1 Revenue by Manufacturers
3.2.1 Global Neurofibromatosis Type 1 Revenue by Manufacturers (2019-2024)
3.2.2 Global Neurofibromatosis Type 1 Revenue Market Share by Manufacturers (2019-2024)
3.2.3 Global Top 10 and Top 5 Companies by Neurofibromatosis Type 1 Revenue in 2023
3.3 Global Key Players of Neurofibromatosis Type 1, Industry Ranking, 2022 VS 2023 VS 2024
3.4 Global Neurofibromatosis Type 1 Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Neurofibromatosis Type 1 Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Neurofibromatosis Type 1, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Neurofibromatosis Type 1, Product Offered and Application
3.8 Global Key Manufacturers of Neurofibromatosis Type 1, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Neurofibromatosis Type 1 Sales by Type
4.1.1 Global Neurofibromatosis Type 1 Historical Sales by Type (2019-2024)
4.1.2 Global Neurofibromatosis Type 1 Forecasted Sales by Type (2025-2030)
4.1.3 Global Neurofibromatosis Type 1 Sales Market Share by Type (2019-2030)
4.2 Global Neurofibromatosis Type 1 Revenue by Type
4.2.1 Global Neurofibromatosis Type 1 Historical Revenue by Type (2019-2024)
4.2.2 Global Neurofibromatosis Type 1 Forecasted Revenue by Type (2025-2030)
4.2.3 Global Neurofibromatosis Type 1 Revenue Market Share by Type (2019-2030)
4.3 Global Neurofibromatosis Type 1 Price by Type
4.3.1 Global Neurofibromatosis Type 1 Price by Type (2019-2024)
4.3.2 Global Neurofibromatosis Type 1 Price Forecast by Type (2025-2030)
5 Market Size by Application
5.1 Global Neurofibromatosis Type 1 Sales by Application
5.1.1 Global Neurofibromatosis Type 1 Historical Sales by Application (2019-2024)
5.1.2 Global Neurofibromatosis Type 1 Forecasted Sales by Application (2025-2030)
5.1.3 Global Neurofibromatosis Type 1 Sales Market Share by Application (2019-2030)
5.2 Global Neurofibromatosis Type 1 Revenue by Application
5.2.1 Global Neurofibromatosis Type 1 Historical Revenue by Application (2019-2024)
5.2.2 Global Neurofibromatosis Type 1 Forecasted Revenue by Application (2025-2030)
5.2.3 Global Neurofibromatosis Type 1 Revenue Market Share by Application (2019-2030)
5.3 Global Neurofibromatosis Type 1 Price by Application
5.3.1 Global Neurofibromatosis Type 1 Price by Application (2019-2024)
5.3.2 Global Neurofibromatosis Type 1 Price Forecast by Application (2025-2030)
6 US & Canada
6.1 US & Canada Neurofibromatosis Type 1 Market Size by Type
6.1.1 US & Canada Neurofibromatosis Type 1 Sales by Type (2019-2030)
6.1.2 US & Canada Neurofibromatosis Type 1 Revenue by Type (2019-2030)
6.2 US & Canada Neurofibromatosis Type 1 Market Size by Application
6.2.1 US & Canada Neurofibromatosis Type 1 Sales by Application (2019-2030)
6.2.2 US & Canada Neurofibromatosis Type 1 Revenue by Application (2019-2030)
6.3 US & Canada Neurofibromatosis Type 1 Market Size by Country
6.3.1 US & Canada Neurofibromatosis Type 1 Revenue by Country: 2019 VS 2023 VS 2030
6.3.2 US & Canada Neurofibromatosis Type 1 Sales by Country (2019-2030)
6.3.3 US & Canada Neurofibromatosis Type 1 Revenue by Country (2019-2030)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe Neurofibromatosis Type 1 Market Size by Type
7.1.1 Europe Neurofibromatosis Type 1 Sales by Type (2019-2030)
7.1.2 Europe Neurofibromatosis Type 1 Revenue by Type (2019-2030)
7.2 Europe Neurofibromatosis Type 1 Market Size by Application
7.2.1 Europe Neurofibromatosis Type 1 Sales by Application (2019-2030)
7.2.2 Europe Neurofibromatosis Type 1 Revenue by Application (2019-2030)
7.3 Europe Neurofibromatosis Type 1 Market Size by Country
7.3.1 Europe Neurofibromatosis Type 1 Revenue by Country: 2019 VS 2023 VS 2030
7.3.2 Europe Neurofibromatosis Type 1 Sales by Country (2019-2030)
7.3.3 Europe Neurofibromatosis Type 1 Revenue by Country (2019-2030)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China Neurofibromatosis Type 1 Market Size
8.1.1 China Neurofibromatosis Type 1 Sales (2019-2030)
8.1.2 China Neurofibromatosis Type 1 Revenue (2019-2030)
8.2 China Neurofibromatosis Type 1 Market Size by Application
8.2.1 China Neurofibromatosis Type 1 Sales by Application (2019-2030)
8.2.2 China Neurofibromatosis Type 1 Revenue by Application (2019-2030)
9 Asia (excluding China)
9.1 Asia Neurofibromatosis Type 1 Market Size by Type
9.1.1 Asia Neurofibromatosis Type 1 Sales by Type (2019-2030)
9.1.2 Asia Neurofibromatosis Type 1 Revenue by Type (2019-2030)
9.2 Asia Neurofibromatosis Type 1 Market Size by Application
9.2.1 Asia Neurofibromatosis Type 1 Sales by Application (2019-2030)
9.2.2 Asia Neurofibromatosis Type 1 Revenue by Application (2019-2030)
9.3 Asia Neurofibromatosis Type 1 Sales by Region
9.3.1 Asia Neurofibromatosis Type 1 Revenue by Region: 2019 VS 2023 VS 2030
9.3.2 Asia Neurofibromatosis Type 1 Revenue by Region (2019-2030)
9.3.3 Asia Neurofibromatosis Type 1 Sales by Region (2019-2030)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Neurofibromatosis Type 1 Market Size by Type
10.1.1 Middle East, Africa and Latin America Neurofibromatosis Type 1 Sales by Type (2019-2030)
10.1.2 Middle East, Africa and Latin America Neurofibromatosis Type 1 Revenue by Type (2019-2030)
10.2 Middle East, Africa and Latin America Neurofibromatosis Type 1 Market Size by Application
10.2.1 Middle East, Africa and Latin America Neurofibromatosis Type 1 Sales by Application (2019-2030)
10.2.2 Middle East, Africa and Latin America Neurofibromatosis Type 1 Revenue by Application (2019-2030)
10.3 Middle East, Africa and Latin America Neurofibromatosis Type 1 Sales by Country
10.3.1 Middle East, Africa and Latin America Neurofibromatosis Type 1 Revenue by Country: 2019 VS 2023 VS 2030
10.3.2 Middle East, Africa and Latin America Neurofibromatosis Type 1 Revenue by Country (2019-2030)
10.3.3 Middle East, Africa and Latin America Neurofibromatosis Type 1 Sales by Country (2019-2030)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Company Profiles
11.1 AstraZeneca
11.1.1 AstraZeneca Company Information
11.1.2 AstraZeneca Overview
11.1.3 AstraZeneca Neurofibromatosis Type 1 Sales, Price, Revenue and Gross Margin (2019-2024)
11.1.4 AstraZeneca Neurofibromatosis Type 1 Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 AstraZeneca Recent Developments
11.2 Merck
11.2.1 Merck Company Information
11.2.2 Merck Overview
11.2.3 Merck Neurofibromatosis Type 1 Sales, Price, Revenue and Gross Margin (2019-2024)
11.2.4 Merck Neurofibromatosis Type 1 Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Merck Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Neurofibromatosis Type 1 Industry Chain Analysis
12.2 Neurofibromatosis Type 1 Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Neurofibromatosis Type 1 Production Mode & Process
12.4 Neurofibromatosis Type 1 Sales and Marketing
12.4.1 Neurofibromatosis Type 1 Sales Channels
12.4.2 Neurofibromatosis Type 1 Distributors
12.5 Neurofibromatosis Type 1 Customers
13 Market Dynamics
13.1 Neurofibromatosis Type 1 Industry Trends
13.2 Neurofibromatosis Type 1 Market Drivers
13.3 Neurofibromatosis Type 1 Market Challenges
13.4 Neurofibromatosis Type 1 Market Restraints
14 Key Findings in The Global Neurofibromatosis Type 1 Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
FEATURED COMPANIES
Astrazeneca plc
Merck
List of Tables
    Table 1. Global Neurofibromatosis Type 1 Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
    Table 2. Major Manufacturers of 10 mg
    Table 3. Major Manufacturers of 25 mg
    Table 4. Global Neurofibromatosis Type 1 Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)
    Table 5. Global Neurofibromatosis Type 1 Revenue Grow Rate (CAGR) by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 6. Global Neurofibromatosis Type 1 Revenue by Region (2019-2024) & (US$ Million)
    Table 7. Global Neurofibromatosis Type 1 Revenue by Region (2025-2030) & (US$ Million)
    Table 8. Global Neurofibromatosis Type 1 Revenue Market Share by Region (2019-2024)
    Table 9. Global Neurofibromatosis Type 1 Revenue Market Share by Region (2025-2030)
    Table 10. Global Neurofibromatosis Type 1 Sales Grow Rate (CAGR) by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 11. Global Neurofibromatosis Type 1 Sales by Region (2019-2024) & (K Units)
    Table 12. Global Neurofibromatosis Type 1 Sales by Region (2025-2030) & (K Units)
    Table 13. Global Neurofibromatosis Type 1 Sales Market Share by Region (2019-2024)
    Table 14. Global Neurofibromatosis Type 1 Sales Market Share by Region (2025-2030)
    Table 15. Global Neurofibromatosis Type 1 Sales by Manufacturers (2019-2024) & (K Units)
    Table 16. Global Neurofibromatosis Type 1 Sales Share by Manufacturers (2019-2024)
    Table 17. Global Neurofibromatosis Type 1 Revenue by Manufacturers (2019-2024) & (US$ Million)
    Table 18. Global Neurofibromatosis Type 1 Revenue Share by Manufacturers (2019-2024)
    Table 19. Global Key Players of Neurofibromatosis Type 1, Industry Ranking, 2022 VS 2023 VS 2024
    Table 20. Neurofibromatosis Type 1 Price by Manufacturers 2019-2024 (US$/Unit)
    Table 21. Global Neurofibromatosis Type 1 Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 22. Global Neurofibromatosis Type 1 by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurofibromatosis Type 1 as of 2023)
    Table 23. Global Key Manufacturers of Neurofibromatosis Type 1, Manufacturing Base Distribution and Headquarters
    Table 24. Global Key Manufacturers of Neurofibromatosis Type 1, Product Offered and Application
    Table 25. Global Key Manufacturers of Neurofibromatosis Type 1, Date of Enter into This Industry
    Table 26. Mergers & Acquisitions, Expansion Plans
    Table 27. Global Neurofibromatosis Type 1 Sales by Type (2019-2024) & (K Units)
    Table 28. Global Neurofibromatosis Type 1 Sales by Type (2025-2030) & (K Units)
    Table 29. Global Neurofibromatosis Type 1 Sales Share by Type (2019-2024)
    Table 30. Global Neurofibromatosis Type 1 Sales Share by Type (2025-2030)
    Table 31. Global Neurofibromatosis Type 1 Revenue by Type (2019-2024) & (US$ Million)
    Table 32. Global Neurofibromatosis Type 1 Revenue by Type (2025-2030) & (US$ Million)
    Table 33. Global Neurofibromatosis Type 1 Revenue Share by Type (2019-2024)
    Table 34. Global Neurofibromatosis Type 1 Revenue Share by Type (2025-2030)
    Table 35. Neurofibromatosis Type 1 Price by Type (2019-2024) & (US$/Unit)
    Table 36. Global Neurofibromatosis Type 1 Price Forecast by Type (2025-2030) & (US$/Unit)
    Table 37. Global Neurofibromatosis Type 1 Sales by Application (2019-2024) & (K Units)
    Table 38. Global Neurofibromatosis Type 1 Sales by Application (2025-2030) & (K Units)
    Table 39. Global Neurofibromatosis Type 1 Sales Share by Application (2019-2024)
    Table 40. Global Neurofibromatosis Type 1 Sales Share by Application (2025-2030)
    Table 41. Global Neurofibromatosis Type 1 Revenue by Application (2019-2024) & (US$ Million)
    Table 42. Global Neurofibromatosis Type 1 Revenue by Application (2025-2030) & (US$ Million)
    Table 43. Global Neurofibromatosis Type 1 Revenue Share by Application (2019-2024)
    Table 44. Global Neurofibromatosis Type 1 Revenue Share by Application (2025-2030)
    Table 45. Neurofibromatosis Type 1 Price by Application (2019-2024) & (US$/Unit)
    Table 46. Global Neurofibromatosis Type 1 Price Forecast by Application (2025-2030) & (US$/Unit)
    Table 47. US & Canada Neurofibromatosis Type 1 Sales by Type (2019-2024) & (K Units)
    Table 48. US & Canada Neurofibromatosis Type 1 Sales by Type (2025-2030) & (K Units)
    Table 49. US & Canada Neurofibromatosis Type 1 Revenue by Type (2019-2024) & (US$ Million)
    Table 50. US & Canada Neurofibromatosis Type 1 Revenue by Type (2025-2030) & (US$ Million)
    Table 51. US & Canada Neurofibromatosis Type 1 Sales by Application (2019-2024) & (K Units)
    Table 52. US & Canada Neurofibromatosis Type 1 Sales by Application (2025-2030) & (K Units)
    Table 53. US & Canada Neurofibromatosis Type 1 Revenue by Application (2019-2024) & (US$ Million)
    Table 54. US & Canada Neurofibromatosis Type 1 Revenue by Application (2025-2030) & (US$ Million)
    Table 55. US & Canada Neurofibromatosis Type 1 Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 56. US & Canada Neurofibromatosis Type 1 Revenue by Country (2019-2024) & (US$ Million)
    Table 57. US & Canada Neurofibromatosis Type 1 Revenue by Country (2025-2030) & (US$ Million)
    Table 58. US & Canada Neurofibromatosis Type 1 Sales by Country (2019-2024) & (K Units)
    Table 59. US & Canada Neurofibromatosis Type 1 Sales by Country (2025-2030) & (K Units)
    Table 60. Europe Neurofibromatosis Type 1 Sales by Type (2019-2024) & (K Units)
    Table 61. Europe Neurofibromatosis Type 1 Sales by Type (2025-2030) & (K Units)
    Table 62. Europe Neurofibromatosis Type 1 Revenue by Type (2019-2024) & (US$ Million)
    Table 63. Europe Neurofibromatosis Type 1 Revenue by Type (2025-2030) & (US$ Million)
    Table 64. Europe Neurofibromatosis Type 1 Sales by Application (2019-2024) & (K Units)
    Table 65. Europe Neurofibromatosis Type 1 Sales by Application (2025-2030) & (K Units)
    Table 66. Europe Neurofibromatosis Type 1 Revenue by Application (2019-2024) & (US$ Million)
    Table 67. Europe Neurofibromatosis Type 1 Revenue by Application (2025-2030) & (US$ Million)
    Table 68. Europe Neurofibromatosis Type 1 Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 69. Europe Neurofibromatosis Type 1 Revenue by Country (2019-2024) & (US$ Million)
    Table 70. Europe Neurofibromatosis Type 1 Revenue by Country (2025-2030) & (US$ Million)
    Table 71. Europe Neurofibromatosis Type 1 Sales by Country (2019-2024) & (K Units)
    Table 72. Europe Neurofibromatosis Type 1 Sales by Country (2025-2030) & (K Units)
    Table 73. China Neurofibromatosis Type 1 Sales by Type (2019-2024) & (K Units)
    Table 74. China Neurofibromatosis Type 1 Sales by Type (2025-2030) & (K Units)
    Table 75. China Neurofibromatosis Type 1 Revenue by Type (2019-2024) & (US$ Million)
    Table 76. China Neurofibromatosis Type 1 Revenue by Type (2025-2030) & (US$ Million)
    Table 77. China Neurofibromatosis Type 1 Sales by Application (2019-2024) & (K Units)
    Table 78. China Neurofibromatosis Type 1 Sales by Application (2025-2030) & (K Units)
    Table 79. China Neurofibromatosis Type 1 Revenue by Application (2019-2024) & (US$ Million)
    Table 80. China Neurofibromatosis Type 1 Revenue by Application (2025-2030) & (US$ Million)
    Table 81. Asia Neurofibromatosis Type 1 Sales by Type (2019-2024) & (K Units)
    Table 82. Asia Neurofibromatosis Type 1 Sales by Type (2025-2030) & (K Units)
    Table 83. Asia Neurofibromatosis Type 1 Revenue by Type (2019-2024) & (US$ Million)
    Table 84. Asia Neurofibromatosis Type 1 Revenue by Type (2025-2030) & (US$ Million)
    Table 85. Asia Neurofibromatosis Type 1 Sales by Application (2019-2024) & (K Units)
    Table 86. Asia Neurofibromatosis Type 1 Sales by Application (2025-2030) & (K Units)
    Table 87. Asia Neurofibromatosis Type 1 Revenue by Application (2019-2024) & (US$ Million)
    Table 88. Asia Neurofibromatosis Type 1 Revenue by Application (2025-2030) & (US$ Million)
    Table 89. Asia Neurofibromatosis Type 1 Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 90. Asia Neurofibromatosis Type 1 Revenue by Region (2019-2024) & (US$ Million)
    Table 91. Asia Neurofibromatosis Type 1 Revenue by Region (2025-2030) & (US$ Million)
    Table 92. Asia Neurofibromatosis Type 1 Sales by Region (2019-2024) & (K Units)
    Table 93. Asia Neurofibromatosis Type 1 Sales by Region (2025-2030) & (K Units)
    Table 94. Middle East, Africa and Latin America Neurofibromatosis Type 1 Sales by Type (2019-2024) & (K Units)
    Table 95. Middle East, Africa and Latin America Neurofibromatosis Type 1 Sales by Type (2025-2030) & (K Units)
    Table 96. Middle East, Africa and Latin America Neurofibromatosis Type 1 Revenue by Type (2019-2024) & (US$ Million)
    Table 97. Middle East, Africa and Latin America Neurofibromatosis Type 1 Revenue by Type (2025-2030) & (US$ Million)
    Table 98. Middle East, Africa and Latin America Neurofibromatosis Type 1 Sales by Application (2019-2024) & (K Units)
    Table 99. Middle East, Africa and Latin America Neurofibromatosis Type 1 Sales by Application (2025-2030) & (K Units)
    Table 100. Middle East, Africa and Latin America Neurofibromatosis Type 1 Revenue by Application (2019-2024) & (US$ Million)
    Table 101. Middle East, Africa and Latin America Neurofibromatosis Type 1 Revenue by Application (2025-2030) & (US$ Million)
    Table 102. Middle East, Africa and Latin America Neurofibromatosis Type 1 Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 103. Middle East, Africa and Latin America Neurofibromatosis Type 1 Revenue by Country (2019-2024) & (US$ Million)
    Table 104. Middle East, Africa and Latin America Neurofibromatosis Type 1 Revenue by Country (2025-2030) & (US$ Million)
    Table 105. Middle East, Africa and Latin America Neurofibromatosis Type 1 Sales by Country (2019-2024) & (K Units)
    Table 106. Middle East, Africa and Latin America Neurofibromatosis Type 1 Sales by Country (2025-2030) & (K Units)
    Table 107. AstraZeneca Company Information
    Table 108. AstraZeneca Description and Major Businesses
    Table 109. AstraZeneca Neurofibromatosis Type 1 Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 110. AstraZeneca Neurofibromatosis Type 1 Product Model Numbers, Pictures, Descriptions and Specifications
    Table 111. AstraZeneca Recent Developments
    Table 112. Merck Company Information
    Table 113. Merck Description and Major Businesses
    Table 114. Merck Neurofibromatosis Type 1 Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 115. Merck Neurofibromatosis Type 1 Product Model Numbers, Pictures, Descriptions and Specifications
    Table 116. Merck Recent Developments
    Table 117. Key Raw Materials Lists
    Table 118. Raw Materials Key Suppliers Lists
    Table 119. Neurofibromatosis Type 1 Distributors List
    Table 120. Neurofibromatosis Type 1 Customers List
    Table 121. Neurofibromatosis Type 1 Market Trends
    Table 122. Neurofibromatosis Type 1 Market Drivers
    Table 123. Neurofibromatosis Type 1 Market Challenges
    Table 124. Neurofibromatosis Type 1 Market Restraints
    Table 125. Research Programs/Design for This Report
    Table 126. Key Data Information from Secondary Sources
    Table 127. Key Data Information from Primary Sources
List of Figures
    Figure 1. Neurofibromatosis Type 1 Product Picture
    Figure 2. Global Neurofibromatosis Type 1 Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 3. Global Neurofibromatosis Type 1 Market Share by Type in 2023 & 2030
    Figure 4. 10 mg Product Picture
    Figure 5. 25 mg Product Picture
    Figure 6. Global Neurofibromatosis Type 1 Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 7. Global Neurofibromatosis Type 1 Market Share by Application in 2023 & 2030
    Figure 8. Hospitals
    Figure 9. Clinics
    Figure 10. Others
    Figure 11. Neurofibromatosis Type 1 Report Years Considered
    Figure 12. Global Neurofibromatosis Type 1 Revenue, (US$ Million), 2019 VS 2023 VS 2030
    Figure 13. Global Neurofibromatosis Type 1 Revenue 2019-2030 (US$ Million)
    Figure 14. Global Neurofibromatosis Type 1 Revenue Market Share by Region in Percentage: 2023 Versus 2030
    Figure 15. Global Neurofibromatosis Type 1 Revenue Market Share by Region (2019-2030)
    Figure 16. Global Neurofibromatosis Type 1 Sales 2019-2030 ((K Units)
    Figure 17. Global Neurofibromatosis Type 1 Sales Market Share by Region (2019-2030)
    Figure 18. US & Canada Neurofibromatosis Type 1 Sales YoY (2019-2030) & (K Units)
    Figure 19. US & Canada Neurofibromatosis Type 1 Revenue YoY (2019-2030) & (US$ Million)
    Figure 20. Europe Neurofibromatosis Type 1 Sales YoY (2019-2030) & (K Units)
    Figure 21. Europe Neurofibromatosis Type 1 Revenue YoY (2019-2030) & (US$ Million)
    Figure 22. China Neurofibromatosis Type 1 Sales YoY (2019-2030) & (K Units)
    Figure 23. China Neurofibromatosis Type 1 Revenue YoY (2019-2030) & (US$ Million)
    Figure 24. Asia (excluding China) Neurofibromatosis Type 1 Sales YoY (2019-2030) & (K Units)
    Figure 25. Asia (excluding China) Neurofibromatosis Type 1 Revenue YoY (2019-2030) & (US$ Million)
    Figure 26. Middle East, Africa and Latin America Neurofibromatosis Type 1 Sales YoY (2019-2030) & (K Units)
    Figure 27. Middle East, Africa and Latin America Neurofibromatosis Type 1 Revenue YoY (2019-2030) & (US$ Million)
    Figure 28. The Neurofibromatosis Type 1 Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2023
    Figure 29. The Top 5 and 10 Largest Manufacturers of Neurofibromatosis Type 1 in the World: Market Share by Neurofibromatosis Type 1 Revenue in 2023
    Figure 30. Global Neurofibromatosis Type 1 Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
    Figure 31. Global Neurofibromatosis Type 1 Sales Market Share by Type (2019-2030)
    Figure 32. Global Neurofibromatosis Type 1 Revenue Market Share by Type (2019-2030)
    Figure 33. Global Neurofibromatosis Type 1 Sales Market Share by Application (2019-2030)
    Figure 34. Global Neurofibromatosis Type 1 Revenue Market Share by Application (2019-2030)
    Figure 35. US & Canada Neurofibromatosis Type 1 Sales Market Share by Type (2019-2030)
    Figure 36. US & Canada Neurofibromatosis Type 1 Revenue Market Share by Type (2019-2030)
    Figure 37. US & Canada Neurofibromatosis Type 1 Sales Market Share by Application (2019-2030)
    Figure 38. US & Canada Neurofibromatosis Type 1 Revenue Market Share by Application (2019-2030)
    Figure 39. US & Canada Neurofibromatosis Type 1 Revenue Share by Country (2019-2030)
    Figure 40. US & Canada Neurofibromatosis Type 1 Sales Share by Country (2019-2030)
    Figure 41. U.S. Neurofibromatosis Type 1 Revenue (2019-2030) & (US$ Million)
    Figure 42. Canada Neurofibromatosis Type 1 Revenue (2019-2030) & (US$ Million)
    Figure 43. Europe Neurofibromatosis Type 1 Sales Market Share by Type (2019-2030)
    Figure 44. Europe Neurofibromatosis Type 1 Revenue Market Share by Type (2019-2030)
    Figure 45. Europe Neurofibromatosis Type 1 Sales Market Share by Application (2019-2030)
    Figure 46. Europe Neurofibromatosis Type 1 Revenue Market Share by Application (2019-2030)
    Figure 47. Europe Neurofibromatosis Type 1 Revenue Share by Country (2019-2030)
    Figure 48. Europe Neurofibromatosis Type 1 Sales Share by Country (2019-2030)
    Figure 49. Germany Neurofibromatosis Type 1 Revenue (2019-2030) & (US$ Million)
    Figure 50. France Neurofibromatosis Type 1 Revenue (2019-2030) & (US$ Million)
    Figure 51. U.K. Neurofibromatosis Type 1 Revenue (2019-2030) & (US$ Million)
    Figure 52. Italy Neurofibromatosis Type 1 Revenue (2019-2030) & (US$ Million)
    Figure 53. Russia Neurofibromatosis Type 1 Revenue (2019-2030) & (US$ Million)
    Figure 54. China Neurofibromatosis Type 1 Sales Market Share by Type (2019-2030)
    Figure 55. China Neurofibromatosis Type 1 Revenue Market Share by Type (2019-2030)
    Figure 56. China Neurofibromatosis Type 1 Sales Market Share by Application (2019-2030)
    Figure 57. China Neurofibromatosis Type 1 Revenue Market Share by Application (2019-2030)
    Figure 58. Asia Neurofibromatosis Type 1 Sales Market Share by Type (2019-2030)
    Figure 59. Asia Neurofibromatosis Type 1 Revenue Market Share by Type (2019-2030)
    Figure 60. Asia Neurofibromatosis Type 1 Sales Market Share by Application (2019-2030)
    Figure 61. Asia Neurofibromatosis Type 1 Revenue Market Share by Application (2019-2030)
    Figure 62. Asia Neurofibromatosis Type 1 Revenue Share by Region (2019-2030)
    Figure 63. Asia Neurofibromatosis Type 1 Sales Share by Region (2019-2030)
    Figure 64. Japan Neurofibromatosis Type 1 Revenue (2019-2030) & (US$ Million)
    Figure 65. South Korea Neurofibromatosis Type 1 Revenue (2019-2030) & (US$ Million)
    Figure 66. China Taiwan Neurofibromatosis Type 1 Revenue (2019-2030) & (US$ Million)
    Figure 67. Southeast Asia Neurofibromatosis Type 1 Revenue (2019-2030) & (US$ Million)
    Figure 68. India Neurofibromatosis Type 1 Revenue (2019-2030) & (US$ Million)
    Figure 69. Middle East, Africa and Latin America Neurofibromatosis Type 1 Sales Market Share by Type (2019-2030)
    Figure 70. Middle East, Africa and Latin America Neurofibromatosis Type 1 Revenue Market Share by Type (2019-2030)
    Figure 71. Middle East, Africa and Latin America Neurofibromatosis Type 1 Sales Market Share by Application (2019-2030)
    Figure 72. Middle East, Africa and Latin America Neurofibromatosis Type 1 Revenue Market Share by Application (2019-2030)
    Figure 73. Middle East, Africa and Latin America Neurofibromatosis Type 1 Revenue Share by Country (2019-2030)
    Figure 74. Middle East, Africa and Latin America Neurofibromatosis Type 1 Sales Share by Country (2019-2030)
    Figure 75. Brazil Neurofibromatosis Type 1 Revenue (2019-2030) & (US$ Million)
    Figure 76. Mexico Neurofibromatosis Type 1 Revenue (2019-2030) & (US$ Million)
    Figure 77. Turkey Neurofibromatosis Type 1 Revenue (2019-2030) & (US$ Million)
    Figure 78. Israel Neurofibromatosis Type 1 Revenue (2019-2030) & (US$ Million)
    Figure 79. GCC Countries Neurofibromatosis Type 1 Revenue (2019-2030) & (US$ Million)
    Figure 80. Neurofibromatosis Type 1 Value Chain
    Figure 81. Neurofibromatosis Type 1 Production Process
    Figure 82. Channels of Distribution
    Figure 83. Distributors Profiles
    Figure 84. Bottom-up and Top-down Approaches for This Report
    Figure 85. Data Triangulation
    Figure 86. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$4900

This license allows only one user to access the PDF.
Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Bioinformatics Barcelona

SIMILAR REPORTS

Global Neurofibromatosis Treatment Drug Market Insights Forecast to 2030
Global Plexiform Neurofibromas Treatment Market Research Report 2025
Global Direct to consumer Disease Risk and Health Genetic Test Market Insights Forecast to 2030
Global Non Rhabdomyosarcoma Treatment Market Research Report 2025
Global Albinism Drug Market Insights Forecast to 2030
Global Disease Risk and Health Genetic Test Market Insights Forecast to 2030
Netherton Syndrome Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Direct to consumer Disease Risk and Health DNA Test Market Insights Forecast to 2030
Global Neurometabolic Disorders Market Insights Forecast to 2030
Global Disease Risk and Health DNA Test Market Insights Forecast to 2030
Global Fragile X Syndrome Testing Market Research Report 2024
Immunotherapy for Neuroblastoma Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Fabry Disease Treatment Market Insights Forecast to 2030
Global Direct to consumer Disease Risk and Health Test Market Insights Forecast to 2030
Global Neuroblastoma Treatment Drugs Market Research Report 2025
Global Rare NGR1 Fusion Market Research Report 2024
Netherton Syndrome Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Alpha 1 Lung Disease Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Cystic Fibrosis CF Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Retinitis Pigmentosa Retinitis Market Insights Forecast to 2030

RELATED REPORTS

Global Lysosomal Storage Disease Treatment Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-17R1241
Mon Sep 15 00:00:00 UTC 2025

Add to Cart

Global Klippel Trenaunay Syndrome Treatment Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-20L1035
Mon Sep 15 00:00:00 UTC 2025

Add to Cart

Global Cystic Fibrosis (Mucoviscoidosis) Testing Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-24R5886
Mon Sep 08 00:00:00 UTC 2025

Add to Cart

Global Lysosomal Storage Diseases Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-34Q5936
Mon Sep 08 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions